Ling Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ling Wang has a total of 175 co-authors. Here are the top co-authors by number of shared publications:
Duancheng Zhao
Joint International Research Laboratory of Synthetic Biology and Medicine, Ministry of Education, Guangdong Provincial Key Laboratory of Fermentation and Enzyme Engineering, Guangdong Provincial Engineering and Technology Research Center of Biopharmaceuticals, School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China
13 shared publications- Ji-Quan Zhang
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Provincial Key Laboratory of Innovation and Manufacturing for Pharmaceuticals, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang 561113, P. R. China
12 shared publications Yihao Chen
Joint International Research Laboratory of Synthetic Biology and Medicine Ministry of Education Guangdong Provincial Key Laboratory of Fermentation and Enzyme Engineering Guangdong Provincial Engineering and Technology Research Center of Biopharmaceuticals School of Biology and Biological Engineering South China University of Technology Guangzhou 510006 China
12 shared publicationsHanxuan Cai
School of Biology and Biological Engineering, South China University of Technology, Guangzhou, 510006, China
11 shared publicationsJindi Huang
Joint International Research Laboratory of Synthetic Biology and Medicine Ministry of Education Guangdong Provincial Key Laboratory of Fermentation and Enzyme Engineering Guangdong Provincial Engineering and Technology Research Center of Biopharmaceuticals School of Biology and Biological Engineering South China University of Technology Guangzhou 510006 China
7 shared publicationsJingxing Wu
Guangdong Provincial Key Laboratory of Fermentation and Enzyme Engineering, Joint International Research Laboratory of Synthetic Biology and Medicine, Guangdong Provincial Engineering and Technology Research Center of Biopharmaceuticals, School of Biology and Biological Engineering, South China University of Technology, Guangzhou, China
7 shared publications
Latest Publications
- Open Access
- 16 July 2026
- Published by Elsevier in SSRN Electronic Journal
Discovery of novel dual-target CDK12/PARP1 inhibitors for the treatment of triple-negative breast cancer
Triple-negative breast cancer (TNBC) represents a highly aggressive breast cancer subtype characterized by a paucity of effective therapeutic options. Consequently, the development of targeted therapies constitutes a promising strategy for TNBC treatment. It has been demonstrated that combining CDK12 and PARP1 inhibitors can trigger synthetic lethality in TNBC cells. In the present study, employing a pharmacophore fusion strategy, we designed and synthesized a series of dual-target inhibitors against CDK12 and PARP1. Among them, compound 20b exerted potent inhibition activity against both CDK12 and PARP1 at nanomolar concentrations. It exhibited markedly superior antiproliferative effects compared with single-target inhibitors and effectively reduced pSer2-CTD (Ser2 phosphorylation) and PAR levels in TNBC cells. Furthermore, compound 20b produced robust colony formation inhibitory effects in TNBC cell lines, accompanied by cell cycle arrest and apoptosis induction. The dual-target CDK12/PARP1 inhibitor 20b developed herein represents a novel lead molecule for TNBC drug development.
- 16 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDiscovery of novel dual-target CDK12/PARP1 inhibitors for the treatment of triple-negative breast cancer
Triple-negative breast cancer (TNBC) represents a highly aggressive breast cancer subtype characterized by a paucity of effective therapeutic options. Consequently, the development of targeted therapies constitutes a promising strategy for TNBC treatment. It has been demonstrated that combining CDK12 and PARP1 inhibitors can trigger synthetic lethality in TNBC cells. In the present study, employing a pharmacophore fusion strategy, we designed and synthesized a series of dual-target inhibitors against CDK12 and PARP1. Among them, compound 20b exerted potent inhibition activity against both CDK12 and PARP1 at nanomolar concentrations. It exhibited markedly superior antiproliferative effects compared with single-target inhibitors and effectively reduced pSer2-CTD (Ser2 phosphorylation) and PAR levels in TNBC cells. Furthermore, compound 20b produced robust colony formation inhibitory effects in TNBC cell lines, accompanied by cell cycle arrest and apoptosis induction. The dual-target CDK12/PARP1 inhibitor 20b developed herein represents a novel lead molecule for TNBC drug development.
- Open Access
- 27 January 2026
- Published by Wiley in Advanced Science
- Vol. 13 (12) , e13099
DualPG‐DTA: A Large Language Model‐Powered Graph Neural Network Framework for Enhanced Drug‐Target Affinity Prediction and Discovery of Novel CDK9 Inhibitors Exhibiting In Vivo Anti‐Leukemia Activity
Accurate prediction of drug‐target interactions constitutes a crucial foundation for drug discovery. DualPG‐DTA is presented, a general framework for binding affinity prediction that integrates two pre‐trained language models to generate atomic‐level molecular representations and residue‐level protein embeddings. The architecture constructs dual molecular‐protein graphs processed through dedicated graph neural networks equipped with dynamic attention mechanisms to extract context‐aware sequence‐level features, which are fused via a multimodal module for affinity predictions. Benchmark results show that DualPG‐DTA consistently outperforms existing models across all metrics. Applied to CDK9 inhibitor discovery, the framework is used to develop robust regression/classification models and identified compound C1 as a novel CDK9 inhibitor with an IC 50 of 1.2 nM. C1 demonstrates exceptional CDK family selectivity alongside optimal pharmacokinetic properties, including prolonged half‐life, adequate clearance, robust plasma exposure, and oral bioavailability. Notably, oral C1 demonstrated potent antitumor efficacy in a Venetoclax‐resistant MV4‐11 acute myeloid leukemia (AML) xenograft model, with concurrent demonstration of favorable tolerability and safety profiles. Collectively, the study not only establishes a unified framework for precise binding affinity prediction but also identifies C1 as a highly promising therapeutic lead targeting CDK9 to conquer Venetoclax resistance in AML.
- 27 January 2026
- Published by Wiley in Advanced Science
- Vol. 13 (12) , e13099
Open AccessDualPG‐DTA: A Large Language Model‐Powered Graph Neural Network Framework for Enhanced Drug‐Target Affinity Prediction and Discovery of Novel CDK9 Inhibitors Exhibiting In Vivo Anti‐Leukemia Activity
Accurate prediction of drug‐target interactions constitutes a crucial foundation for drug discovery. DualPG‐DTA is presented, a general framework for binding affinity prediction that integrates two pre‐trained language models to generate atomic‐level molecular representations and residue‐level protein embeddings. The architecture constructs dual molecular‐protein graphs processed through dedicated graph neural networks equipped with dynamic attention mechanisms to extract context‐aware sequence‐level features, which are fused via a multimodal module for affinity predictions. Benchmark results show that DualPG‐DTA consistently outperforms existing models across all metrics. Applied to CDK9 inhibitor discovery, the framework is used to develop robust regression/classification models and identified compound C1 as a novel CDK9 inhibitor with an IC 50 of 1.2 nM. C1 demonstrates exceptional CDK family selectivity alongside optimal pharmacokinetic properties, including prolonged half‐life, adequate clearance, robust plasma exposure, and oral bioavailability. Notably, oral C1 demonstrated potent antitumor efficacy in a Venetoclax‐resistant MV4‐11 acute myeloid leukemia (AML) xenograft model, with concurrent demonstration of favorable tolerability and safety profiles. Collectively, the study not only establishes a unified framework for precise binding affinity prediction but also identifies C1 as a highly promising therapeutic lead targeting CDK9 to conquer Venetoclax resistance in AML.
- 13 January 2026
- Published by Elsevier in Science Bulletin
- Vol. 71 (5) , 1176-1194
Pharmacotranscriptomics-based discovery and hydrogel-mediated delivery of drug combinations for potentiated cancer immunotherapy
- 13 January 2026
- Published by Elsevier in Science Bulletin
- Vol. 71 (5) , 1176-1194
Pharmacotranscriptomics-based discovery and hydrogel-mediated delivery of drug combinations for potentiated cancer immunotherapy
- 5 January 2026
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 66 (2) , 1116-1129
Deciphering the Atomic Mechanisms of Third-Generation Bisteric mTOR Inhibitors through Comparative Microsecond Molecular Dynamics Simulations
The mammalian target of rapamycin (mTOR) is a central regulator of cell growth and a key cancer therapeutic target. Although first-generation allosteric and second-generation ATP-competitive mTOR inhibitors have been developed, resistance due to mTOR mutations remains a challenge. Third-generation bisteric inhibitors, which bridge both allosteric and orthosteric sites via a flexible linker, offer a promising solution, yet their atomic mechanisms and optimal linker design are not fully understood. Here, we performed microsecond molecular dynamics simulations on six mTOR-bisteric inhibitor complexes. Our results reveal that (1) steric inhibitors stabilize the catalytic cleft of mTOR, (2) inhibitor potency correlates with cleft closure, and (3) optimal linker length promotes a more closed and stable conformation, enhancing binding affinity. These findings provide atomic-level insights to guide the rational design of next-generation mTOR inhibitors.
- 5 January 2026
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 66 (2) , 1116-1129
Deciphering the Atomic Mechanisms of Third-Generation Bisteric mTOR Inhibitors through Comparative Microsecond Molecular Dynamics Simulations
The mammalian target of rapamycin (mTOR) is a central regulator of cell growth and a key cancer therapeutic target. Although first-generation allosteric and second-generation ATP-competitive mTOR inhibitors have been developed, resistance due to mTOR mutations remains a challenge. Third-generation bisteric inhibitors, which bridge both allosteric and orthosteric sites via a flexible linker, offer a promising solution, yet their atomic mechanisms and optimal linker design are not fully understood. Here, we performed microsecond molecular dynamics simulations on six mTOR-bisteric inhibitor complexes. Our results reveal that (1) steric inhibitors stabilize the catalytic cleft of mTOR, (2) inhibitor potency correlates with cleft closure, and (3) optimal linker length promotes a more closed and stable conformation, enhancing binding affinity. These findings provide atomic-level insights to guide the rational design of next-generation mTOR inhibitors.
- Open Access
- 6 November 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (D1) , D1488-D1499
MGDB: a curated database for molecular glues
Molecular glues (MGs) represent a unique class of small molecules that modulate protein–protein interactions by altering target protein surface properties, enabling targeted degradation, pathway modulation, or functional control of proteins, including traditionally undruggable targets. Currently, 17 MG-based drugs are approved globally with over 40 in clinical trials, underscoring their therapeutic potential. Despite these advances, the lack of a dedicated database integrating structural, pharmacological, and computational data for such compounds hinders rational drug design. To address this gap, we developed MGDB, a specialized open-access repository integrating rigorously curated multidimensional data for MGs. MGDB contains 7396 curated MGs being sourced from 162 peer-reviewed publications and 156 patents. It consolidates structural data, 9728 experimental bioactivity data points (covering degradation efficiency, binding affinity, cellular/animal activity) across 201 targets and 108 effectors, 115 296 computed physicochemical properties, and 270 785 ADMET profiles. The database supports text-based and chemical structure-based queries and interoperability with external resources (e.g. PubChem, ChEMBL, DrugBank, UniProt, and WIPO) via hyperlinks. By centralizing and standardizing specialized MG information, MGDB empowers researchers to rapidly explore MG research landscapes and provides high-quality datasets for artificial intelligence-driven rational therapeutic design. MGDB is freely available at http://mgdb.idruglab.cn/.
- 6 November 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (D1) , D1488-D1499
Open AccessMGDB: a curated database for molecular glues
Molecular glues (MGs) represent a unique class of small molecules that modulate protein–protein interactions by altering target protein surface properties, enabling targeted degradation, pathway modulation, or functional control of proteins, including traditionally undruggable targets. Currently, 17 MG-based drugs are approved globally with over 40 in clinical trials, underscoring their therapeutic potential. Despite these advances, the lack of a dedicated database integrating structural, pharmacological, and computational data for such compounds hinders rational drug design. To address this gap, we developed MGDB, a specialized open-access repository integrating rigorously curated multidimensional data for MGs. MGDB contains 7396 curated MGs being sourced from 162 peer-reviewed publications and 156 patents. It consolidates structural data, 9728 experimental bioactivity data points (covering degradation efficiency, binding affinity, cellular/animal activity) across 201 targets and 108 effectors, 115 296 computed physicochemical properties, and 270 785 ADMET profiles. The database supports text-based and chemical structure-based queries and interoperability with external resources (e.g. PubChem, ChEMBL, DrugBank, UniProt, and WIPO) via hyperlinks. By centralizing and standardizing specialized MG information, MGDB empowers researchers to rapidly explore MG research landscapes and provides high-quality datasets for artificial intelligence-driven rational therapeutic design. MGDB is freely available at http://mgdb.idruglab.cn/.
- Open Access
- 13 September 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (7) , 4166-4195
Computation-driven discovery of novel chromone derivatives for the treatment of triple-negative breast cancer via mTOR-targeted inhibition and triggering antitumor immunity
- 13 September 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (7) , 4166-4195
Open AccessComputation-driven discovery of novel chromone derivatives for the treatment of triple-negative breast cancer via mTOR-targeted inhibition and triggering antitumor immunity
- Open Access
PDCNet: a benchmark and general deep learning framework for activity prediction of peptide-drug conjugates
Peptide-drug conjugates (PDCs) represent a promising therapeutic avenue for human diseases, particularly in cancer treatment. Systematic elucidation of structure-activity relationships (SARs) and accurate prediction of the activity of PDCs are critical for the rational design and optimization of these conjugates. To this end, we carefully design and construct a benchmark PDCs dataset compiled from literature-derived collections and PDCdb database, and then develop PDCNet, the first unified deep learning framework for forecasting the activity of PDCs. The architecture systematically captures the complex factors underlying anticancer decisions of PDCs in real-word scenarios through a multi-level feature fusion framework that collaboratively characterizes and learns the features of peptides, linkers, and payloads. Leveraging a curated PDCs benchmark dataset, comprehensive evaluation results show that PDCNet demonstrates superior predictive capability, with the highest AUC, F1, MCC and BA scores of 0.9213, 0.7656, 0.7071 and 0.8388 for the test set, outperforming eight established traditional machine learning models. Multi-level validations, including 5-fold cross-validation, threshold testing, ablation studies, model interpretability analysis and external independent testing, further confirm the superiority, robustness, and usability of the PDCNet architecture. We anticipate that PDCNet represents a novel paradigm, incorporating both a benchmark dataset and advanced models, which can accelerate the design and discovery of new PDC-based therapeutic agents.
Open AccessPDCNet: a benchmark and general deep learning framework for activity prediction of peptide-drug conjugates
Peptide-drug conjugates (PDCs) represent a promising therapeutic avenue for human diseases, particularly in cancer treatment. Systematic elucidation of structure-activity relationships (SARs) and accurate prediction of the activity of PDCs are critical for the rational design and optimization of these conjugates. To this end, we carefully design and construct a benchmark PDCs dataset compiled from literature-derived collections and PDCdb database, and then develop PDCNet, the first unified deep learning framework for forecasting the activity of PDCs. The architecture systematically captures the complex factors underlying anticancer decisions of PDCs in real-word scenarios through a multi-level feature fusion framework that collaboratively characterizes and learns the features of peptides, linkers, and payloads. Leveraging a curated PDCs benchmark dataset, comprehensive evaluation results show that PDCNet demonstrates superior predictive capability, with the highest AUC, F1, MCC and BA scores of 0.9213, 0.7656, 0.7071 and 0.8388 for the test set, outperforming eight established traditional machine learning models. Multi-level validations, including 5-fold cross-validation, threshold testing, ablation studies, model interpretability analysis and external independent testing, further confirm the superiority, robustness, and usability of the PDCNet architecture. We anticipate that PDCNet represents a novel paradigm, incorporating both a benchmark dataset and advanced models, which can accelerate the design and discovery of new PDC-based therapeutic agents.
- 26 May 2025
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 65 (11) , 5255-5272
NA-DB: An Online Database of Nucleoside Analogues
Nucleoside analogues (NAs) constitute a class of compounds that mirror the structure of natural nucleosides but undergo chemical modifications, rendering them an important compound resource for drug development as exogenous substitutes for natural nucleosides. Nevertheless, the design of novel NA-based drugs remains a great challenge due to the complexity of asymmetric synthesis and restrained chemical space owing to the strict requirement of hydrogen boding pattern of nucleotides. To facilitate the rational design of NA drugs, we build a specialized database named NA-DB to integrate both structural and annotated biological information about NAs reported in literatures. The database contains around 9074 NAs, which are composed of 4513 base-like fragments and 2602 ribose-like fragments, and a user-friendly web interface is provided to search chemical and biological information on NAs as well as their structural features corresponding to the base and ribose moieties. Simultaneously, multiple analyses were conducted to aid in a comprehensive understanding of the structural characteristics of NAs within the database. NA-DB is freely accessible at http://nadb.idruglab.cn/.
- 26 May 2025
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 65 (11) , 5255-5272
NA-DB: An Online Database of Nucleoside Analogues
Nucleoside analogues (NAs) constitute a class of compounds that mirror the structure of natural nucleosides but undergo chemical modifications, rendering them an important compound resource for drug development as exogenous substitutes for natural nucleosides. Nevertheless, the design of novel NA-based drugs remains a great challenge due to the complexity of asymmetric synthesis and restrained chemical space owing to the strict requirement of hydrogen boding pattern of nucleotides. To facilitate the rational design of NA drugs, we build a specialized database named NA-DB to integrate both structural and annotated biological information about NAs reported in literatures. The database contains around 9074 NAs, which are composed of 4513 base-like fragments and 2602 ribose-like fragments, and a user-friendly web interface is provided to search chemical and biological information on NAs as well as their structural features corresponding to the base and ribose moieties. Simultaneously, multiple analyses were conducted to aid in a comprehensive understanding of the structural characteristics of NAs within the database. NA-DB is freely accessible at http://nadb.idruglab.cn/.
- Open Access
- 3 May 2025
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 26 (3)
ADCNet: a unified framework for predicting the activity of antibody-drug conjugates
Antibody-drug conjugates (ADCs) have revolutionized the field of cancer treatment in the era of precision medicine due to their ability to precisely target cancer cells and release highly effective drugs. Nevertheless, the rational design and discovery of ADCs remain challenging because the relationship between their quintuple structures and activities is difficult to explore and understand. To address this issue, we first introduce a unified deep learning framework called ADCNet to explore such relationship and help design potential ADCs. The ADCNet highly integrates the protein representation learning language model ESM-2 and small-molecule representation learning language model functional group-based bidirectional encoder representations from transformers to achieve activity prediction through learning meaningful features from antigen and antibody protein sequences of ADC, SMILES strings of linker and payload, and drug-antibody ratio (DAR) value. Based on a carefully designed and manually tailored ADC data set, extensive evaluation results reveal that ADCNet performs best on the test set compared to baseline machine learning models across all evaluation metrics. For example, it achieves an average prediction accuracy of 87.12%, a balanced accuracy of 0.8689, and an area under receiver operating characteristic curve of 0.9293 on the test set. In addition, cross-validation, ablation experiments, and external independent testing results further prove the stability, advancement, and robustness of the ADCNet architecture. For the convenience of the community, we develop the first online platform (https://ADCNet.idruglab.cn) for the prediction of ADCs activity based on the optimal ADCNet model, and the source code is publicly available at https://github.com/idrugLab/ADCNet.
- 3 May 2025
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 26 (3)
Open AccessADCNet: a unified framework for predicting the activity of antibody-drug conjugates
Antibody-drug conjugates (ADCs) have revolutionized the field of cancer treatment in the era of precision medicine due to their ability to precisely target cancer cells and release highly effective drugs. Nevertheless, the rational design and discovery of ADCs remain challenging because the relationship between their quintuple structures and activities is difficult to explore and understand. To address this issue, we first introduce a unified deep learning framework called ADCNet to explore such relationship and help design potential ADCs. The ADCNet highly integrates the protein representation learning language model ESM-2 and small-molecule representation learning language model functional group-based bidirectional encoder representations from transformers to achieve activity prediction through learning meaningful features from antigen and antibody protein sequences of ADC, SMILES strings of linker and payload, and drug-antibody ratio (DAR) value. Based on a carefully designed and manually tailored ADC data set, extensive evaluation results reveal that ADCNet performs best on the test set compared to baseline machine learning models across all evaluation metrics. For example, it achieves an average prediction accuracy of 87.12%, a balanced accuracy of 0.8689, and an area under receiver operating characteristic curve of 0.9293 on the test set. In addition, cross-validation, ablation experiments, and external independent testing results further prove the stability, advancement, and robustness of the ADCNet architecture. For the convenience of the community, we develop the first online platform (https://ADCNet.idruglab.cn) for the prediction of ADCs activity based on the optimal ADCNet model, and the source code is publicly available at https://github.com/idrugLab/ADCNet.
- 7 April 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 160, 108436
Design, synthesis and bio-evaluation of 2,5-disubstituted thiazole derivatives for potential treatment of acute myeloid leukemia through targeting CDK9
- 7 April 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 160, 108436
Design, synthesis and bio-evaluation of 2,5-disubstituted thiazole derivatives for potential treatment of acute myeloid leukemia through targeting CDK9